PMC:7319919 / 6691-7025 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T40","span":{"begin":203,"end":211},"obj":"Disease"}],"attributes":[{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Declaration of Competing Interest\nDavid Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. The rest of the authors are sub-investigators in this project. All authors declare no other competing interests."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T68","span":{"begin":86,"end":87},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Declaration of Competing Interest\nDavid Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. The rest of the authors are sub-investigators in this project. All authors declare no other competing interests."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T52","span":{"begin":153,"end":172},"obj":"Chemical"},{"id":"T53","span":{"begin":153,"end":162},"obj":"Chemical"},{"id":"T54","span":{"begin":163,"end":172},"obj":"Chemical"},{"id":"T55","span":{"begin":174,"end":182},"obj":"Chemical"}],"attributes":[{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_45783"}],"text":"Declaration of Competing Interest\nDavid Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. The rest of the authors are sub-investigators in this project. All authors declare no other competing interests."}

{"project":"LitCovid-PubTator","denotations":[{"id":"167","span":{"begin":212,"end":220},"obj":"Species"},{"id":"168","span":{"begin":153,"end":172},"obj":"Chemical"},{"id":"169","span":{"begin":174,"end":182},"obj":"Chemical"},{"id":"170","span":{"begin":188,"end":199},"obj":"Chemical"},{"id":"171","span":{"begin":203,"end":211},"obj":"Disease"}],"attributes":[{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"Tax:9606"},{"id":"A168","pred":"tao:has_database_id","subj":"168","obj":"MESH:C558899"},{"id":"A169","pred":"tao:has_database_id","subj":"169","obj":"MESH:D000068877"},{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"MESH:C000596027"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Declaration of Competing Interest\nDavid Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. The rest of the authors are sub-investigators in this project. All authors declare no other competing interests."}

{"project":"LitCovid-sentences","denotations":[{"id":"T51","span":{"begin":0,"end":33},"obj":"Sentence"},{"id":"T52","span":{"begin":34,"end":221},"obj":"Sentence"},{"id":"T53","span":{"begin":222,"end":284},"obj":"Sentence"},{"id":"T54","span":{"begin":285,"end":334},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Declaration of Competing Interest\nDavid Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. The rest of the authors are sub-investigators in this project. All authors declare no other competing interests."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T94","span":{"begin":153,"end":162},"obj":"DG_23"},{"id":"T95","span":{"begin":163,"end":172},"obj":"DG_30"},{"id":"T96","span":{"begin":174,"end":182},"obj":"CHEBI:14434;CHEBI:14434"},{"id":"T97","span":{"begin":188,"end":199},"obj":"DG_41"},{"id":"T98","span":{"begin":203,"end":211},"obj":"SP_7"},{"id":"T99569","span":{"begin":153,"end":162},"obj":"DG_23"},{"id":"T38180","span":{"begin":163,"end":172},"obj":"DG_30"},{"id":"T67623","span":{"begin":174,"end":182},"obj":"CHEBI:14434;CHEBI:14434"},{"id":"T63693","span":{"begin":188,"end":199},"obj":"DG_41"},{"id":"T80737","span":{"begin":203,"end":211},"obj":"SP_7"}],"text":"Declaration of Competing Interest\nDavid Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. The rest of the authors are sub-investigators in this project. All authors declare no other competing interests."}